Singapore markets open in 3 hours 51 minutes
Straits Times Index
3,239.03 +26.39 (+0.82%) S&P 500
3,977.53 +6.54 (+0.16%) Dow
32,432.08 +194.55 (+0.60%) Nasdaq
11,768.84 -55.12 (-0.47%) Bitcoin USD
27,088.18 -699.60 (-2.52%) CMC Crypto 200
587.32 -20.14 (-3.32%)
AZN Oct 2023 72.500 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:12PM EDT. Market open.
| Previous close | 6.87 |
| Open | 5.80 |
| Bid | 5.90 |
| Ask | 6.15 |
| Strike | 72.50 |
| Expiry date | 2023-10-20 |
| Day's range | 5.80 - 5.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 157 |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
